Bai Yunshan responded to the Medical Insurance Bureau notification: Rectified persons have been rectified and suspended from office

Cover News Profile reporter Tan Yuqing

On August 10, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. issued an announcement in response to the "Notice on the Price of Three Enterprises in Tianxin Pharmaceuticals, including Tianxin Pharmaceuticals, and other bidding prices of drug prices, and the prices related to the funds related to funds" released by the State Medical Security Bureau It is said that the subordinate branches involved in the notification have been rectified, and the responsible persons of the branch have been exempt from office.

Yesterday, the State Medical Insurance Bureau's "Notice" pointed out that from 2017 to May 2021, three pharmaceutical manufacturers including Tianxin Pharmaceuticals were in order to avoid the "two -vote" policies and supervision, and they had more than 50 pharmaceutical agents in the lower reaches. 87 kinds of drugs such as cephalosporin sulfur are used to use virtual high -priced prices to purchase raw materials, and transfer funds to downstream drug agents.

According to today's announcement, the Baiyunshan Pharmaceutical Group has instructed the cooperation with relevant agents and dealers in Baiyunshan Pharmaceutical General Plant, Tianxin Pharmaceutical and Jingxiu Pharmaceuticals, and comprehensively rectify the marketing model to conduct nationwide. Related products reduced prices or withdrawn from the net.

As of press time, Baiyunshan's stock plummeted 3.90%to 27.33 yuan per share.

- END -